Healthcare, Pharma & Life Sciences

STOCKHOLM – October 30, 2026 -- The Nomination Committee of Swedish Orphan Biovitrum AB (Sobi) proposes Börje Ekholm, who recently stepped down as CEO of Ericsson, as new Board member and Chair at the 2027 Annual General Meeting (AGM). He would succeed David Meek, who has told the committee he will not stand for re-election.

Meek stays on as Chair until May 2027

Meek has served on Sobi's Board and as Chair since December 2024 and will remain Chair for the rest of his term, which runs to May 2027. The committee credits his tenure with strong growth and shareholder return, wider patient access through new launches and indication extensions, and a stronger clinical development pipeline.

SCOTTSDALE, Ariz. – October 30, 2026 -- LifeStance Health (Nasdaq: LFST) reports that 74% of its patients with treatment-resistant depression achieved a clinically meaningful reduction in symptoms after 12 weeks of esketamine (Spravato), while 61% of TMS patients improved after at least 30 sessions. The outpatient mental healthcare provider is expanding access to both specialty services across the U.S.

Esketamine analysis covers 258 patients and shows suicidal ideation falling to 2%

LifeStance tracked progress with the Patient Health Questionnaire (PHQ-9). It defines clinically meaningful improvement as a score reduction of five or more points.

Among the 258 esketamine patients, the share reporting suicidal ideation nearly every day fell from 13% before treatment to 2% afterward, an 85% reduction.

SHANGHAI – October 30, 2026 -- Phrontline Biopharma reported partial responses in six of eight response-evaluable urothelial carcinoma patients (75%) treated with its bispecific antibody-drug conjugate (ADC) TJ101, and has dosed the first patient in a Phase Ib trial.

TJ101 produces responses in patients previously treated with EV and pembrolizumab

The data were presented at the ESMO Congress 2026 in Madrid on October 23, 2026. Responders included patients previously treated with enfortumab vedotin (EV) and pembrolizumab. The results are preliminary and come from a small patient group. The company itself cautions that such findings may not predict outcomes in later studies.

Boston – October 30, 2026 -- Bambusa Therapeutics (Nasdaq: BBTX) priced its upsized initial public offering at $16.00 per share, raising expected gross proceeds of $168,888,880 from the sale of 10,555,555 common shares.

Underwriters hold a 30-day option on 1,583,333 additional shares

The clinical-stage biopharmaceutical company granted its underwriters the option to buy up to 1,583,333 more shares at the IPO price, less underwriting discounts and commissions. Bambusa is the sole seller; all shares in the offering come from the company. The gross figure is before underwriting discounts, commissions and other offering expenses.

Trading on Nasdaq Global Select Market begins October 30

Shares are expected to start trading on October 30, 2026, under the ticker BBTX. The offering is expected to close on November 2, 2026, subject to customary closing conditions.

Rochester, N.Y. -- AeroSafe Global will host a virtual Sustainability Symposium on November 10, 2026, to present closed-loop reuse systems for cold-chain packaging that it says can cut landfill waste by up to 95%.

Single academic medical center handles nearly 300,000 pounds of gel packs a year

The event targets single-use cold-chain packaging as a contributor to the healthcare waste stream. According to AeroSafe, one academic medical center can process nearly 300,000 pounds of single-use gel packs annually. The session will test whether circular delivery models and reverse logistics can remove that waste at source while keeping thermal integrity intact for critical therapies.

Minnesota – October 30, 2026 -- UCare, a nonprofit Minnesota health plan, recovered $2.1 million in additional advance premium tax credit (APTC) reimbursements after partnering with Softheon to replace manual shopping, enrollment and billing processes.

Manual processes had blocked UCare's On-Exchange scaling and Off-Exchange entry

UCare said manual workflows in shopping, enrollment and billing limited its ability to scale On-Exchange operations. The same constraints held back its expansion into the Off-Exchange market. UCare turned to Softheon to address both the scalability problem and the time-consuming manual work, with the aim of improving its health plan offerings and member experience.

APTC reconciliation accuracy rose 2.5%, driving the $2.1 million gain

The 2.5% improvement in APTC reconciliation accuracy produced the $2.1 million in extra reimbursements, the largest financial result UCare reported.

Stockholm – October 30, 2026 -- Eisai will present five years of Clarity AD data on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026, according to its partner BioArctic AB (Nasdaq Stockholm: BIOA B). The dataset spans the core and long-term extension phases and is one of the longest follow-up sets reported to date for an approved anti-amyloid Alzheimer's therapy.

LEADER study tests lecanemab in US clinical practice three years after approval

A symposium on Wednesday, November 18, 11:00-11:40 AM ET, will cover the retrospective, multicenter LEADER study. The study draws on real-world data from different types of US treatment centers, three years after FDA approval.

Three analyses are scheduled: utilization and outcomes from initiation through maintenance therapy, sex-based outcomes, and at-home subcutaneous administration.

Shanghai – October 30, 2026 -- aphranel®, the regenerative aesthetics brand of MOYOM Biotech, has brought European physicians to China for a week-long clinical exchange, following NMPA Class III approval for its MagiCCrystal CaHA filler in China in 2025 and EU MDR certification in 2026.

Delegation visits seven clinics across four Chinese cities

Dr. Tiago Guimarães and the aphranel® European Medical and Sales Team toured facilities with aphranel®-certified Chinese physicians. Stops included Yestar Medical Aesthetic Hospital and Huamei Zixin Medical Aesthetic Hospital in Guangzhou, and Shenzhen Fanyan Aesthetics and Shenzhen Boai Shuguang Hospital in Shenzhen. The group also visited REAL Medical Aesthetics in Shanghai, and Estee Ryan and JollyHue in Hangzhou.

The programme runs under the banner "Learning in China, Applying in Europe" and forms part of The Norns' Weave, a global academic initiative for physicians.

East Rutherford – October 30, 2026 -- Cambrex has started construction on a $120 million expansion at its Charles City, Iowa, facility, adding 160,000 liters of manufacturing capacity for small molecule active pharmaceutical ingredients (APIs) and synthetic peptides.

Expansion lifts Charles City capacity by about 25% to nearly one million liters

The contract development and manufacturing organization (CDMO) expects to complete the project in the fourth quarter of 2028. The added volume raises the site's total capacity by approximately 25%, to nearly one million liters.

Cambrex held a groundbreaking ceremony on October 29 with company leaders, employees, state and local officials and members of the Charles City community. The start of construction coincides with the site's 100th anniversary.

SAN ANTONIO – October 30, 2026 -- A new national coalition, The Pet Variable, will lobby to have the human-animal bond recognized as a social determinant of health (SDoH) in federal, state and local policy, citing research that up to 70% of American families include a pet.

The group launches with nine founding members across public health, veterinary medicine, housing, social services, research and policy. They are CARE (Companions and Animals for Reform and Equity), Annie & Millie's Place, RedRover, BestyBnB, My Dog is My Home, the Massachusetts Society for the Prevention of Cruelty to Animals (MSPCA), Ohio State's College of Veterinary Medicine, JVR Strategies and The Pet Vet Connection.